ERCC1 expression and variants in genes involved in DNA repair pathways and in etoposide pharmacokinetics may be predictors of efficacy and toxicity to PE-based treatment [18,22,24,27], but data concerning SCLC are insufficient and inconsistent [29,30,31]. The gene discussed is ERCC1; the disease is small cell lung carcinoma.